Latest Headlines

31. Asimov Launches CHO Edge Rapid Pools To Bridge Biologics Discovery And CMC With Predictive Stable Expression 12/16/2025

    Asimov, the synthetic biology company advancing the design and manufacture of therapeutics, today announced the launch of CHO Edge Rapid Pools, a high-throughput stable CHO expression system that brings CMC-grade performance and assurance to biologics discovery teams.

32. Bora Pharmaceuticals And Corealis Pharma Forge Strategic Alliance To Deliver Seamless, End-To-End Oral Solid Dose Development 12/9/2025

    Bora Pharmaceuticals Co., Ltd. (“Bora”, TWSE: 6472), a global leader in pharmaceutical manufacturing, and Corealis Pharma Inc., a leading early-phase Contract Development Manufacturing Organization (CDMO), have entered into a strategic alliance to provide end-to-end services for oral solid dose (OSD) development and manufacturing. The collaboration will simplify the drug development process and provide a more scalable pathway to commercialization via a single continuum.

33. Late-Model Lab & Bioprocess Equipment From Premier Biopharma Facility To Be Offered For Sale December 4–9, 2025 12/8/2025
34. Andelyn Biosciences Announces Partnership With Jaguar Gene Therapy To Provide Late-Stage PPQ Manufacturing 12/8/2025

    Andelyn Biosciences, a leading and patient-focused cell and gene therapy Contract Development and Manufacturing Organization (CDMO), has partnered with Jaguar Gene Therapy to perform late-stage Process Performance Qualification (PPQ) manufacturing of JAG201, an investigational gene therapy targeting SHANK3 haploinsufficiency which is clinically diagnosed as Phelan-McDermid syndrome (PMS), a leading monogenic cause of autism spectrum disorder (ASD).

35. Bora Pharmaceuticals Marks Five Years In Mississauga, Canada, Strengthening Its Commitment To Onshore And Global CDMO Excellence 12/5/2025

    Bora Pharmaceuticals Co., Ltd. (“Bora” or “the Company”, TWSE: 6472), a global leader in pharmaceutical manufacturing, today celebrates the five-year anniversary of its Mississauga, Ontario, Canada facility, a key hub in the company’s North American operations and a cornerstone of its expanding international CDMO network. The milestone will be celebrated onsite with employees, partners, and community stakeholders.

36. medac CDMO Supports Urogen Pharma's Advancement Of UGN-103 11/24/2025

    This collaboration reflects a commitment to advancing meaningful therapies and ensuring patients worldwide gain access to effective, reliable treatment options.

37. Equipment Auction Announced For Sutro Biopharma Assets 11/24/2025

    December 15-16, 2025: Featuring late-model lab, R&D and manufacturing equipment surplus to future needs of Sutro BioPharma: spray dryer, chromatography systems, Westfalia seperators, HPLC’s & more.

38. Solid Biosciences Announces Licensing Agreement With Andelyn Biosciences For The Use Of Proprietary Next-Generation Capsid AAV-SLB101 11/17/2025

    Solid Biosciences Inc. (Nasdaq: SLDB) (the “Company” or “Solid”), a life sciences company developing precision genetic medicines for neuromuscular and cardiac diseases, today announced a non-exclusive worldwide license and collaboration agreement with Andelyn Biosciences (Andelyn), a pioneering and patient-focused cell and gene therapy Contract Development and Manufacturing Organization (CDMO), for the use of Solid’s proprietary, next-generation capsid, AAV-SLB101.

39. Re:Build Manufacturing Launches Ensorcell To Engineer And Manufacture Innovative And Affordable Life Science Tools 11/11/2025
40. AES Cleanroom Technology Establishes New Office In Research Triangle Park To Support Regional Drug Manufacturing Growth 11/11/2025

    AES Cleanroom Technology, an award-winning leader in modular cleanroom design and construction, has opened a new regional office in Research Triangle Park (RTP), reinforcing its commitment to serving the Southeast’s fast-growing life sciences, biotechnology, and advanced manufacturing sectors.